Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones
- 1 December 1995
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 4 (12), 1299-1309
- https://doi.org/10.1517/13543784.4.12.1299
Abstract
To date, the treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM) has focused primarily on attempts to correct some of the metabolic abnormalities commonly associated with the disease. Insulin and/or insulin secretagogues, such as sulphonylureas, are frequently used to lower blood sugar; however, there is a significant risk of hypoglycaemia. Moreover, the use of insulin or insulin secretagogues in patients who are already hyperinsulinaemic may accelerate some of the cardiovascular complications of NIDDM, and further aggravate insulin resistance. Other therapeutic strategies have focused on aberrations in glucose metabolism or absorption, including biguanides, such as metformin, or glucosidase inhibitors, such as acarbose. While these agents have been efficacious to a degree, they do not have a direct impact on the underlying pathology of insulin resistance. A novel therapeutic strategy involves the use of insulin-sensitising agents, such as the thiazolidinediones. These compounds appear to improve insulin resistance by enhancing insulin action in skeletal muscle, liver and adipose tissue. Recent preclinical studies have revealed key insights into the potential mechanism of action of the thiazolidinediones. Furthermore, the emerging clinical experience with one of these agents, troglitazone, is substantiating the benefits of these agents in insulin-resistant diseases.Keywords
This publication has 28 references indexed in Scilit:
- Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the RatDiabetes, 1994
- A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the RatDiabetes, 1994
- Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.Hypertension, 1994
- Antihypertensive effects of CS-045 treatment in obese Zucker ratsMetabolism, 1993
- Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats.Endocrine Journal, 1993
- Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemiaMetabolism, 1991
- The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker ratsMetabolism, 1991
- Glucose Transport Deficiency in Diabetic Animals Is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone*Endocrinology, 1991
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988
- Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agentDiabetes, 1983